Pascalite Clay Powder Deodorant Recall (F-1127-2013)
Pascalite, Incorporated recalled its clay powder product after FDA testing found violative levels of lead. The product was sold in 8 oz, 16 oz, 5 lb, and 25 lb containers and marketed for use as a deodorant and freshener. The recall was initiated in January 2013 and terminated in April 2013.
By RecallRadar Editorial Team
Sourced from FDA. Last verified April 24, 2026.
On this page
Free checker
Check if you qualify
See whether your device may qualify for a free repair or replacement program before you spend money.
Check if you qualifyKey facts
- Date announced
- January 2, 2013
- Source agency
- FDA
This recall affects device functionality. Consider taking action soon.
✨ Plain-English Summary
Pascalite, Incorporated recalled its clay powder product after FDA testing found violative levels of lead. The product was sold in 8 oz, 16 oz, 5 lb, and 25 lb containers and marketed for use as a deodorant and freshener. The recall was initiated in January 2013 and terminated in April 2013.
Is This Recall Still Active?
Status: No - Expired
This recall is no longer active. You can still review details here for historical reference and confirmation.
What's Being Recalled
Quoted source excerpt from the official notice.
Pascalite Clay Powder recalled because it may contain violative levels of lead. The powder was marketed as a deodorant and freshener.
Quick Info
Key facts from the official notice, kept in the article flow for easy cross-checking.
- Brand
- Pascalite
- Category
- food
- Source agency
- FDA
- Announced
- January 2, 2013
- Country
- US
- Status
- Expired
Who's Affected
Specific models and identifiers listed in the source notice:
Model #1
All Pascalite powder products in 8 oz, 16 oz, 5 lb, and 25 lb containers
| # | Model |
|---|---|
| 1 | All Pascalite powder products in 8 oz, 16 oz, 5 lb, and 25 lb containers |
Technical model codes are manufacturer identifiers. Match both the product name and model code from your device settings, label, or packaging.
What You Should Do
Follow the remedy path from the official notice using the exact model and serial details above.
- 1Stop using Pascalite Clay Powder immediately.
- 2Do not apply to skin or use as a deodorant.
- 3Keep the product out of reach of children.
- 4Contact Pascalite at 307-347-3872 for disposal instructions.
This program has ended. The official source page may no longer be available.
Source & Verification
This page summarizes the official notice and keeps key facts easy to verify.
- Official source
- FDA
- Announced by source
- January 2, 2013
- Last reviewed by RecallRadar
- April 24, 2026
Frequently Asked Questions
Am I affected by this recall?
Check the affected models section on this page. The official notice currently lists All Pascalite powder products in 8 oz, 16 oz, 5 lb, and 25 lb containers.
What is the remedy for this recall?
1. Stop using Pascalite Clay Powder immediately. 2. Do not apply to skin or use as a deodorant. 3. Keep the product out of reach of children. 4. Contact Pascalite at 307-347-3872 for disposal instructions. 5. Consult a healthcare provider if you have concerns about lead exposure.
Where can I verify recall details?
Use the official source link in this page to confirm dates, eligibility, and next steps: https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts
Keep browsing with these internal hubs: Pascalite recall hub and Food & Drug recall hub.
Official Resources
Use these primary sources for final eligibility and claim instructions.
View official notice from FDASee an inaccuracy?
Help us improve the accuracy of this recall information.
On this page
Free checker
Check if you qualify
See whether your device may qualify for a free repair or replacement program before you spend money.
Check if you qualifyKey facts
- Date announced
- January 2, 2013
- Source agency
- FDA
Related Recalls
Metoclopramide Tablets, USP, 5 mg, 100 Tablets (10 x 10), Rx Only, Distributed by: American Health Packaging, Columbus, Ohio 43217. NDC Carton: 60687-620-01; NDC Unit Dose: 60687-620-11
Presence of Foreign Tablets/Capsules
Oct 21, 2026
Hydrocortisone Sodium Succinate for Injection, USP 100 mg/vial, 1 Vial, Rx Only, Manufactured by: Zydus Lifesciences Ltd., Vadodara - 391510 India, Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534, NDC 70710-1907-1.
Failed Impurities/Degradation Specifications.
Oct 21, 2026
Sermorelin, 1 mg/mL, 10 ml vial, Sterile injectable solution, RX Only, Houston RX LLC, 15430 Vantage Parkway E STE 220, Houston, TX 77032.
Lack of process control
Oct 21, 2026
Metoclopramide Tablets, USP, 5 mg, [100 or 500] Tablets per bottle, Rx Only, Manufactured for: Teva Pharmaceuticals, Parsippany, NJ 07054. NDC 100 Tablets: 0093-2204-01; NDC 500 Tablets: 0093-2204-05
Presence of Foreign Tablets/Capsules
Oct 21, 2026
Tirzepatide/Niacinamide 2mL vial (40 MG per Vial) Inj 20mg/2mg/mL, RX Only, Houston RX LLC, 15430 Vantage Parkway E STE 220, Houston, TX 77032.
Lack of assurance of sterility.
Oct 21, 2026